# US 12,765,937 B2 · Methods, apparatuses, and systems for the treatment of disease states and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,765,937 B2
- Document ID: US12765937B2
- Status: Granted
- Kind: B2
- Application number: 19/453,384
- Filed: 2026-01-20
- Published: 2026-06-04
- Granted: 2026-10-20
- Earliest claimed: 2017-12-26
- Assignees: Galvanize Therapeutics, Inc.
- Applicants: Galvanize Therapeutics, Inc.
- Inventors: Jonathan Reuben Waldstreicher; William Sanford Krimsky; Denise M. Zarins; Robert J. Beetel; Paul Brian Friedrichs; Kevin James Taylor; Roman Turovskiy; Robert E. Neal, II
- Web page: https://patentgrep.com/patent/US12765937B2

## CPC

- A61B 18/1206: {Generators therefor}
- A61N 1/06: for high-frequency therapy
- A61B 1/2676: {Bronchoscopes}
- A61B 2018/0022: {Balloons}
- A61B 2018/00351: {Heart}
- A61B 2018/00541: {Lung or bronchi}
- A61B 2018/124: {switching the output to different electrodes, e.g. sequentially}
- A61B 18/1492: {having a flexible, catheter-like structure, e.g. for heart ablation (A61B18/1477 takes precedence)}
- A61N 1/326: {for promoting growth of cells, e.g. bone cells}
- A61N 1/362: Heart stimulators (heart defibrillators A61N1/39)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and/or other pulmonary diseases or disorders.

## Claims

### Claim 1

A method of treating cancer of a subject in need thereof, the method comprising:
advancing a device comprising an elongate shaft and an electrode into the subject having the cancer, the electrode electrically coupled to a generator programmed with an energy delivery algorithm configured to generate an electric signal having a waveform comprising a plurality of energy packets with a rest period between each energy packet, wherein each energy packet comprises a plurality of biphasic pulses;
penetrating tissue with the device to enter an embedded targeted region in the subject; and
applying pulsed electric field energy via the electrode to the embedded targeted region based on the electric signal generated by the generator to target cancer cells to induce cell death of the cancer cells in a non-thermal manner while maintaining an extracellular matrix in the embedded target region, thereby treating the cancer of the subject,
wherein the electric signal comprises a frequency and a voltage, and wherein an effect of the frequency inversely balances an effect of the voltage so as to target the cancer cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the embedded targeted region is within a lung of the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the embedded targeted region is within a wall of a passageway of the lung.

### Claim 4 (depends on 1)

The method of claim 1, wherein the embedded targeted region is at a blood vessel, a lymphatic vessel, a bile duct, a kidney tubule, an esophagus, a stomach, a small intestine, a large intestine, an appendix, a rectum, a bladder, a ureter, a pharynx, a mouth, a vagina, a urethra, or a duct of a gland.

### Claim 5 (depends on 1)

The method of claim 1, wherein the energy delivery algorithm has a number of energy packets of the plurality of energy packets to increase lethality of the applied pulsed electric field energy to the cancer cells relative to healthy cells exposed to the pulsed electric field energy.

### Claim 6 (depends on 1)

The method of claim 1, wherein the energy delivery algorithm is configured to cause application of the pulsed electric field energy while inhibiting muscle contraction.

### Claim 7 (depends on 1)

The method of claim 1, further comprising correlating impedance measurements from test pulses to impedance values measured during the applying of the pulsed electric field energy to avoid electric current flow and concentration that induces electroporation.

### Claim 8 (depends on 1)

The method of claim 1, further comprising monitoring a condition to inhibit electrical arcs.

### Claim 9 (depends on 8)

The method of claim 8, wherein the condition is an impedance measurement between the electrode and a dispersive pad.

### Claim 10 (depends on 1)

The method of claim 1, wherein the pulsed electric field energy is configured to induce the cell death by apoptosis.

### Claim 11 (depends on 1)

The method of claim 1, further comprising placing a dispersive electrode on skin of the subject so that the electrode applies the pulsed electric field energy in a monopolar manner.

### Claim 12 (depends on 1)

The method of claim 1, wherein the elongate shaft is formed in a catheter and the electrode is near a distal end of the catheter.

### Claim 13 (depends on 1)

The method of claim 1, wherein advancing the device into the subject comprising advancing the device through a lumen of a bronchoscope.

### Claim 14 (depends on 13)

The method of claim 13, wherein advancing the device is performed using a robotic bronchoscopy system.

### Claim 15 (depends on 1)

The method of claim 1, wherein the biphasic pulses are separated by a dead time so as to reduce biphasic cancellation.

### Claim 16 (depends on 15)

The method of claim 15, wherein the dead time is up to 100 milliseconds.

### Claim 17 (depends on 1)

The method of claim 1, wherein the rest period between each energy packet is in a range of 0.1 to 5 seconds.

### Claim 18 (depends on 1)

The method of claim 1, wherein the plurality of energy packets comprises up to 100 energy packets.

### Claim 19 (depends on 1)

The method of claim 1, wherein the voltage for the biphasic pulses is in a range of 500 to 4000 V.

### Claim 20 (depends on 1)

The method of claim 1, wherein the frequency for the biphasic pulses is in a range of 100 to 1000 KHz.

### Claim 21 (depends on 1)

The method of claim 1, wherein the electric signal is configured to selectively target the cancer cells while avoiding collateral cells.

### Claim 22 (depends on 1)

The method of claim 1, further comprising sensing information of the subject,
wherein applying the pulsed electric field energy comprises applying the pulsed electric field energy based on the sensed information of the subject.

### Claim 23 (depends on 1)

The method of claim 1, wherein the subject's cancer cells are conditioned to modify behavior of the cancer cells.

### Claim 24 (depends on 23)

The method of claim 23, wherein the conditioning comprises administration of a conditioning solution comprising a cytokine, an immunostimulant, an interleukin, a gene, VEGF, or a cellular differentiating factor.

### Claim 25 (depends on 23)

The method of claim 23, wherein the conditioning occurs prior to, during, or after applying the pulsed electric field energy.

### Claim 26 (depends on 23)

The method of claim 23, wherein the conditioning comprises administration of a conditioning solution comprising a chemotherapy drug.

### Claim 27 (depends on 1)

The method of claim 1, wherein the cell death is caused by immune cell interaction responsive to applying the pulsed electric field energy.

### Claim 28 (depends on 1)

The method of claim 1, further comprising re-positioning the device at another target site and repeating applying the pulsed electric field energy for the treatment.
